EXELIXIS INC
For the period ended Apr 4, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Apr 4, 2025 · Filed May 13, 2025
EXEL$70.58-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $183,752 | $217,374 |
| Marketable securities | 847,564 | 893,902 |
| Trade receivables, net | 281,637 | 265,437 |
| Inventory | 24,853 | 22,388 |
| Prepaid expenses and other current assets | 58,696 | 68,478 |
| Total current assets | 1,396,502 | 1,467,579 |
| Non-current marketable securities | 619,441 | 637,291 |
| Property and equipment, net | 115,030 | 119,391 |
| Deferred tax assets, net | 419,045 | 420,027 |
| Goodwill | 63,684 | 63,684 |
| Right-of-use assets and other non-current assets | 223,545 | 239,718 |
| Total assets | $2,837,247 | $2,947,690 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $42,840 | $38,191 |
| Accrued compensation and benefits | 89,747 | 109,830 |
| Accrued clinical trial liabilities | 57,635 | 57,976 |
| Rebates and fees due to customers | 57,840 | 62,376 |
| Accrued collaboration liabilities | 25,489 | 40,384 |
| Other current liabilities | 125,551 | 95,012 |
| Total current liabilities | 399,102 | 403,769 |
| Non-current operating lease liabilities | 187,125 | 190,823 |
| Other non-current liabilities | 119,996 | 108,895 |
| Total liabilities | 706,223 | 703,487 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued | — | — |
| Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 275,033 and 281,732 at March 31, 2025, and December 31, 2024, respectively | 275 | 282 |
| Additional paid-in-capital | 2,292,033 | 2,343,915 |
| Accumulated other comprehensive income (loss) | 2,010 | (1,347) |
| Accumulated deficit | (163,294) | (98,647) |
| Total stockholders’ equity | 2,131,024 | 2,244,203 |
| Total liabilities and stockholders’ equity | $2,837,247 | $2,947,690 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.